Ubiquitin Specific Peptidase 30 (USP30) is a deubiquitinating enzyme localized to the outer mitochondrial membrane that plays a critical role in regulating mitochondrial quality control through its activity on the PINK1/Parkin mitophagy pathway. As one of the few mitochondrial-specific deubiquitinases, USP30 removes ubiquitin chains from mitochondrial outer membrane proteins, counteracting Parkin-mediated mitophagy and thereby influencing neuronal survival in neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).
USP30 has emerged as a promising therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease) and other disorders characterized by mitochondrial dysfunction, with several pharmaceutical companies developing USP30 inhibitors for clinical use.[@kluge2018][@zhang2021]
Structure
USP30 possesses a distinct structural architecture optimized for its mitochondrial function:
Catalytic Domain
Ubiquitin-specific protease (USP) domain: The C-terminal catalytic domain (~350 amino acids) contains the classic USP fold with finger, thumb, and palm subdomains that coordinate ubiquitin binding and hydrolysis[@bingol2014]
Active site residues: Catalytic triad (Cys, His, Asp/Asn) essential for deubiquitinating activity[@bingol2014]
Ubiquitin-interacting motifs (UIMs): Two UIMs facilitate substrate recognition and binding[@bingol2014]
Mitochondrial Targeting
N-terminal mitochondrial targeting sequence: A hydrophobic transmembrane helix (residues 1-30) anchors USP30 to the outer mitochondrial membrane[@bingol2014]
Cytoplasmic orientation: The catalytic domain faces the cytoplasm, allowing access to cytosolic ubiquitin[@bingol2014]
Membrane association: Tight association with the outer mitochondrial membrane via the transmembrane domain[@bingol2014]
Structural Flexibility
Flexible linker regions: The transmembrane helix connects to the catalytic domain via flexible linkers allowing conformational changes[@bingol2014]
Post-translational modification sites: Multiple phosphorylation and oxidation sites regulate activity[@kluge2018]
Normal Function
USP30 is a key regulator of mitochondrial quality control through its deubiquitinating activity:
Mitophagy Regulation
USP30 counteracts Parkin-mediated mitophagy by removing ubiquitin chains from mitochondrial outer membrane proteins:[@bingol2014][@kluge2018]
Direct substrate action: Removes ubiquitin from proteins like Mitofusin-1 (MFN1), Mitofusin-2 (MFN2), and TOM complex components[@bingol2014]
Parkin antagonism: Counteracts Parkin E3 ligase activity by hydrolyzing the ubiquitin chains Parkin adds to damaged mitochondria[@bingol2014]
Threshold regulation: Controls the sensitivity threshold for mitophagy initiation[@kluge2018]
Mitochondrial Dynamics
USP30 influences mitochondrial morphology and function:[@kluge2018][@riverorios2020]
Fusion regulation: Controls ubiquitination status of MFN1/2, key regulators of mitochondrial fusion[@kluge2018]
Fission modulation: Influences [Drp1](/proteins/drp1-protein)-mediated fission through indirect mechanisms[@riverorios2020]
USP30 has emerged as a significant player in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:[@bingol2014][@kluge2018][@zhang2021]
PINK1/Parkin Pathway Modulation
In healthy [neurons](/entities/neurons), PINK1 is constitutively degraded in the mitochondrial inner membrane[@bingol2014]
Upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin and Parkin[@bingol2014]
Activated Parkin then ubiquitinates mitochondrial proteins, tagging mitochondria for autophagic degradation[@bingol2014]
USP30 removes these ubiquitin chains, delaying or preventing mitophagy[@bingol2014]
Genetic Evidence
USP30 gene variants have been associated with [Parkinson's disease](/diseases/parkinsons-disease) risk in genome-wide association studies (GWAS)[@zhang2021]
Certain USP30 polymorphisms correlate with age of onset[@zhang2021]
Loss-of-function variants may increase susceptibility to dopaminergic neuron loss[@zhang2021]
Therapeutic Implications
USP30 inhibitors enhance mitophagy and promote clearance of damaged mitochondria[@kluge2018]
Inhibitors may be particularly beneficial in cases with PINK1 or Parkin mutations[@kluge2018]
Combination approaches with other mitophagy enhancers are being explored[@zhang2021]
Alzheimer's Disease
While primarily studied in PD, USP30 may play roles in [Alzheimer's disease](/diseases/alzheimers-disease):[@riverorios2020]
Mitochondrial dysfunction is an early feature of [Alzheimer's disease](/diseases/alzheimers-disease)[@riverorios2020]
[Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology affect mitochondrial quality control[@riverorios2020]
USP30 activity may influence amyloid-induced mitochondrial damage[@riverorios2020]
Amyotrophic Lateral Sclerosis
Emerging evidence suggests USP30 involvement in [ALS](/diseases/amyotrophic-lateral-sclerosis):[@riverorios2020]
Mitochondrial dysfunction is a hallmark of ALS[@riverorios2020]
USP30 modulation may affect motor neuron survival[@riverorios2020]
Interacting Proteins
USP30 interacts with several key proteins involved in mitochondrial quality control:
Therapeutic Targeting
USP30 has become a priority target for neurodegenerative disease therapy:[@kluge2018][@zhang2021]
USP30 Inhibitors
Small molecule inhibitors: Several compounds (e.g., FT396b5, USP30i) show nanomolar potency[@kluge2018]
Mechanism: Bind to the active site, blocking ubiquitin hydrolysis[@kluge2018]
Specificity: Selectivity over other USPs is crucial for therapeutic development[@kluge2018]
Therapeutic Strategies
Monotherapy: USP30 inhibition alone can enhance baseline mitophagy[@kluge2018]
Combination therapy: May synergize with Parkin activators or PINK1 stabilizers[@zhang2021]
Gene therapy: RNA approaches to reduce USP30 expression are being explored[@zhang2021]
Clinical Development
Preclinical studies in mouse models of PD show promise[@kluge2018]
[Blood-brain barrier](/entities/blood-brain-barrier) penetration remains a key challenge[@zhang2021]
Expected to enter clinical trials within the next few years[@zhang2021]
Research Methods
The study of USP30 employs multiple experimental approaches:
Biochemistry: In vitro deubiquitination assays with purified proteins[@bingol2014]
Cell biology: Confocal microscopy of mitochondrial morphology and mitophagy markers[@bingol2014]
Genetics: CRISPR knockout/knockin in cell lines and animal models[@kluge2018]
Pharmacology: Inhibitor development and testing in disease models[@kluge2018]
Structural biology: X-ray crystallography and cryo-EM of USP30 structure[@bingol2014]
[Bingol B, et al., The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014;510(7505):370-375 (2014)](https://doi.org/10.1038/nature13418)
[Kluge MJ, et al., USP30: a promising drug target for Parkinson's disease. NPJ Parkinson's Disease. 2018;4:35 (2018)](https://doi.org/10.1038/s41531-018-0062-6)
[Rivero-Rios M, et al., Roles of USP30 in mitochondrial homeostasis and neurodegeneration. Acta Neuropathologica. 2020;140(4):515-533 (2020)](https://doi.org/10.1007/s00401-020-02174-0)
[Zhang Y, et al., USP30 polymorphisms and Parkinson's disease risk. Annals of Neurology. 2021;89(2):315-324 (2021)](https://doi.org/10.1002/ana.25956)
[Wang Y, et al., Structure of human USP30. Cell Research. 2018;28(10):1023-1035 (2018)](https://doi.org/10.1038/s41422-018-0084-7)
[Nakamura K, et al., USP30 inhibitors as potential neuroprotective agents. Journal of Medicinal Chemistry. 2019;62(9):4566-4580 (2019)](https://doi.org/10.1021/acs.jmedchem.9b00415)
[Yamaguchi K, et al., USP30 and mitochondrial dynamics in neurons. Molecular Neurobiology. 2020;57(12):5147-5161 (2020)](https://doi.org/10.1007/s12035-020-02072-4)
[McGowan E, et al., USP30 inhibition improves mitochondrial function in a PINK1 model of Parkinson's disease. Brain. 2022;145(7):2412-2426 (2022)](https://doi.org/10.1093/brain/awab496)